Posts tagged Carol Ann Werther
HCW starts XOMA at buy

H.C. Wainwright initiated coverage of XOMA (NASDAQ:XOMA) with a “buy” rating and $15 price target. The stock closed at $6.86 June 12th.

Read More
HCW starts Catabasis Pharma at buy

H.C. Wainwright initiated coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $14 price target. The stock closed at $3.59 on Dec. 21.

Read More
Wainwright starts Summit Therapeutics at buy

H.C. Wainwright initiated coverage of Summit Therapeutics (NASDAQ:SMMT) with a “buy” rating and $26 price target. The stock closed at $5.50 on Thursday.

Summit has two de-risked assets, with billion-dollar potential, and is conducting clinical programs focused on two genetic diseases: Duchenne muscular dystrophy (DMD) and Clostridium difficile infections (CDI).

Read More